J&J wraps up potential $1B buyout of Aragon Pharmaceuticals

08/20/2013 | PharmaTimes (U.K.) · San Diego Business Journal

Johnson & Johnson has finalized its purchase of Aragon Pharmaceuticals, which is developing a potential treatment for prostate cancer, for $650 million plus $350 million in potential milestone fees. The acquisition gives J&J access to Aragon's androgen receptor antagonist program, including ARN-509, a drug candidate for castration-resistant prostate cancer. The deal "strengthens our prostate cancer pipeline with a second-generation, potentially best-in-class compound," said Peter Lebowitz, J&J's global therapeutic area head of oncology.

View Full Article in:

PharmaTimes (U.K.) · San Diego Business Journal

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
MN
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC